Three-drug combination for advanced leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing a combination of three drugs (FLAG-Ida, venetoclax, and asciminib) to see if it is effective and safe for people with certain types of leukemia (CML in blast phase or Ph+ AML) that are new or have come back after treatment. The goal is to see if this combination can control the disease and possibly lead to remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have either a type of chronic myeloid leukemia (CML) that has progressed to blast phase, or a type of acute myeloid leukemia (AML) that has a specific chromosome change (Philadelphia chromosome).
- You should be in reasonably good physical condition (able to do your daily activities).
- You need to have a recent blood test showing your liver, kidney, and heart function is adequate.
- You need to be willing to use effective birth control during the study.
- If you have chronic hepatitis B, C, or HIV, you must be on treatment and have undetectable virus levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This trial tests a combination of two chemotherapy drugs packaged in a special fat coating (liposome) plus a targeted pill called venetoclax for adults with acute myeloid leukemia (AML) that has come back, not responded, or is newly diagnosed. The goal is to see if this combination is safe and effective.
This trial combines three standard chemotherapy drugs (fludarabine, cytarabine, idarubicin) with a targeted therapy (venetoclax) to treat acute myeloid leukemia (AML) and a related condition called MDS with high blast counts. The goal is to see if adding venetoclax improves results.
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
Hear when a new Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.